Pharma · Private company

Janssen Vaccines & Prevention B.V.

Track this companyFree. Adds Janssen Vaccines & Prevention B.V. to your Dealase workspace and tells you when its record changes.

Clinical trials250 recruiting or active

Pipeline programs46From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline46

Ad26.COV2.SPhase 3 · Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the ProtocolClinicalTrials.gov · fetched Nov 12, 2026
Ad26.COV2.SPhase 3 · COVID-19 PreventionClinicalTrials.gov · fetched Nov 12, 2026
Ad26.RSV.preF-based vaccinePhase 3 · Influenza, Human PreventionClinicalTrials.gov · fetched Nov 12, 2026
Ad26.RSV.preF-based vaccinePhase 3 · Respiratory Syncytial Virus PreventionClinicalTrials.gov · fetched Nov 12, 2026
Ad26.RSV.preF-based VaccinePhase 3 · Respiratory Syncytial Virus Infection PreventionClinicalTrials.gov · fetched Nov 12, 2026
Ad26.ZEBOVPhase 3 · EbolaClinicalTrials.gov · fetched Nov 12, 2026
Ad26.ZEBOV 0.8*10^10 (vp)Phase 3 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Ad26.ZEBOV 2*10^10 (vp)Phase 3 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Ad26.ZEBOV 5*10^10 viral particles (vp)Phase 3 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preFPhase 3 · Respiratory Syncytial VirusesClinicalTrials.gov · fetched Nov 12, 2026
Influenza VaccinePhase 3 · COVID-19 PreventionClinicalTrials.gov · fetched Nov 12, 2026
MVA-BN-FiloPhase 3 · EbolaClinicalTrials.gov · fetched Nov 12, 2026
MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]Phase 3 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
MVA-BN-Filo 5*10^7 Inf. U.Phase 3 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Quadrivalent High-dose Influenza VaccinePhase 3 · Influenza, Human PreventionClinicalTrials.gov · fetched Nov 12, 2026
Ad26.HPV16Phase 2 · Human Papillomavirus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
Ad26.HPV18Phase 2 · Human Papillomavirus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
Ad26.Mos.HIVPhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Ad26.Mos4.HIVPhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Ad26.RSV.preFPhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Ad26.RSV.preF (1*10^11 vp)Phase 2 · Respiratory Syncytial VirusesClinicalTrials.gov · fetched Nov 12, 2026
Ad26.RSV.preF (5*10^10 vp)Phase 2 · Respiratory Syncytial VirusesClinicalTrials.gov · fetched Nov 12, 2026
Ad26.RSV.preF 1*10^11 vpPhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Ad26.ZEBOVPhase 2 · Hemorrhagic Fever, EbolaClinicalTrials.gov · fetched Nov 12, 2026
Al(OH)3Phase 2 · Influenza PreventionClinicalTrials.gov · fetched Nov 12, 2026
Clade C gp140Phase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Clade C gp140 plus adjuvantPhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Clade C gp140/Mosaic gp140 plus adjuvantPhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
FluarixPhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
gp140 DP High-dosePhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
gp140 DP Low-dosePhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
gp140 HIV Bivalent VaccinePhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
INFLUENZA G1 mHAPhase 2 · Influenza PreventionClinicalTrials.gov · fetched Nov 12, 2026
Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcgPhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcgPhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
MVA-BN-FiloPhase 2 · Hemorrhagic Fever, EbolaClinicalTrials.gov · fetched Nov 12, 2026
MVA-MosaicPhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
MVA.HPV16/18Phase 2 · Human Papillomavirus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
RSV preF Protein 150 mcgPhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
RSV preF Protein 50 mcgPhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
RSV preF-based VaccinePhase 2 · Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease PreventionClinicalTrials.gov · fetched Nov 12, 2026
RSV VaccinePhase 2 · Respiratory Syncytial VirusesClinicalTrials.gov · fetched Nov 12, 2026
RSV VaccinePhase 2 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Ad26.Mos4.HIVPhase 1 · Human Immunodeficiency VirusClinicalTrials.gov · fetched Nov 12, 2026
Clade C gp140 + Mosaic gp140Phase 1 · Human Immunodeficiency VirusClinicalTrials.gov · fetched Nov 12, 2026
MVA-MosaicPhase 1 · Human Immunodeficiency VirusClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy AdultsPHASE1_PHASE2 · COMPLETED · started May 17, 2023ClinicalTrials.gov NCT05901636 · fetched Nov 12, 2026
A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and OlderPHASE1_PHASE2 · TERMINATED · started Apr 13, 2022ClinicalTrials.gov NCT05327816 · fetched Nov 12, 2026
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy AdultsPHASE3 · COMPLETED · started Nov 2, 2021ClinicalTrials.gov NCT05091307 · fetched Nov 12, 2026
A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 YearsPHASE3 · COMPLETED · started Nov 1, 2021ClinicalTrials.gov NCT05101486 · fetched Nov 12, 2026
A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years OldPHASE3 · COMPLETED · started Oct 8, 2021ClinicalTrials.gov NCT05083585 · fetched Nov 12, 2026
A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and OlderPHASE3 · COMPLETED · started Oct 4, 2021ClinicalTrials.gov NCT05071313 · fetched Nov 12, 2026
A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV InfectionPHASE3 · COMPLETED · started Sep 29, 2021ClinicalTrials.gov NCT05070546 · fetched Nov 12, 2026
A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)PHASE2 · COMPLETED · started Aug 27, 2021ClinicalTrials.gov NCT04765384 · fetched Nov 12, 2026
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and OlderPHASE3 · COMPLETED · started Jul 21, 2021ClinicalTrials.gov NCT04908683 · fetched Nov 12, 2026
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in AdultsPHASE3 · COMPLETED · started Nov 12, 2020ClinicalTrials.gov NCT04614948 · fetched Nov 12, 2026
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult ParticipantsPHASE3 · COMPLETED · started Sep 7, 2020ClinicalTrials.gov NCT04505722 · fetched Nov 12, 2026
A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older AdultsPHASE2 · COMPLETED · started Jul 16, 2020ClinicalTrials.gov NCT04453202 · fetched Nov 12, 2026
A Study of Ad26.COV2.S in Adults (COVID-19)PHASE1_PHASE2 · COMPLETED · started Jul 15, 2020ClinicalTrials.gov NCT04436276 · fetched Nov 12, 2026
A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult ParticipantsPHASE3 · COMPLETED · started Feb 18, 2020ClinicalTrials.gov NCT04228783 · fetched Nov 12, 2026
A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and OlderPHASE2 · TERMINATED · started Aug 1, 2019ClinicalTrials.gov NCT03982199 · fetched Nov 12, 2026
Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the CervixPHASE1_PHASE2 · TERMINATED · started Sep 27, 2018ClinicalTrials.gov NCT03610581 · fetched Nov 12, 2026
A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and OlderPHASE1_PHASE2 · COMPLETED · started Jul 6, 2018ClinicalTrials.gov NCT03502707 · fetched Nov 12, 2026
A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral TreatmentPHASE1 · COMPLETED · started Mar 5, 2018ClinicalTrials.gov NCT03307915 · fetched Nov 12, 2026
A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable HealthPHASE2 · COMPLETED · started Dec 7, 2017ClinicalTrials.gov NCT03339713 · fetched Nov 12, 2026
A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of AgePHASE1_PHASE2 · COMPLETED · started Nov 29, 2017ClinicalTrials.gov NCT03303625 · fetched Nov 12, 2026
A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected AdultsPHASE1_PHASE2 · COMPLETED · started Mar 31, 2017ClinicalTrials.gov NCT02935686 · fetched Nov 12, 2026
Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected AdultsPHASE1_PHASE2 · COMPLETED · started Jul 8, 2016ClinicalTrials.gov NCT02788045 · fetched Nov 12, 2026
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-FiloPHASE2 · COMPLETED · started Dec 10, 2015ClinicalTrials.gov NCT02598388 · fetched Nov 12, 2026
A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult ParticipantsPHASE3 · COMPLETED · started Sep 21, 2015ClinicalTrials.gov NCT02543567 · fetched Nov 12, 2026
Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) PreventionPHASE1_PHASE2 · COMPLETED · started Dec 22, 2014ClinicalTrials.gov NCT02315703 · fetched Nov 12, 2026